Terms: = Testicular cancer AND Neurokinin
2 results:
1. Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with testicular cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant Interaction.
Strik J; de Jong LAW; Sijm J; Desar IME; van Erp NP
Clin Pharmacol Ther; 2024 Jan; 115(1):135-138. PubMed ID: 37867292
[TBL] [Abstract] [Full Text] [Related]
2. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract] [Full Text] [Related]
